CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Exicure Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Exicure Inc
2430 N. HALSTED ST.
Phone: (847) 673-1700p:847 673-1700 CHICAGO, IL  60614  United States Ticker: XCURXCUR

On November 28, 2023, the Audit Committee of the Board of Directors of Exicure, Inc., after discussions with its management, concluded that financial statements for the quarters ended September 30, 2023, March 31, 2023 and June 30, 2023 should no longer be relied upon. It has been determined that the it was no longer appropriate to record certain research and development expenses with its wind down activities in 2023.

Business Summary
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director PaulKang 61 8/21/2023 2/24/2023
President, Secretary, CEO, CFO & Director IanJacobs
Chief Financial Officer, Company Secretary, Director JiyoungHwang 46 8/21/2023 12/30/2022
6 additional Officers and Directors records available in full report.

Business Names
Business Name
EXCR
Exicure Operating Company
XCUR

General Information
Number of Employees: 7 (As of 6/30/2023)
Outstanding Shares: 8,648,307 (As of 8/9/2023)
Shareholders: 66
Stock Exchange: NASD
Federal Tax Id: 815333008
Fax Number: (847) 556-6411


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024